News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (SNY) Chief Says U.S. Supreme Court Ruling On Biologics Has "Immediate Impact"



6/19/2017 6:33:56 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

The justices, in a 9-0 ruling, overturned a lower court's decision that had prevented Swiss pharmaceutical company Novartis from selling its copycat version of California-based Amgen Neupogen until six months after the U.S Food and drug administration approved it.

The decision has major implications for the pharmaceutical industry because it will dictate how long brand-name makers of biological drugs can keep near-copies, named biosimilars, off the market.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES